Homeopathic Divide: FDA Talks Pre-Market Approval As Industry Floats Label Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA officials point out label changes would not resolve their concerns that homeopathics, unlike other Rx and OTC drug categories, are available without pre-market approval. Stakeholders emphasize the products’ safety while suggesting changes such as more information on labels to better identify ingredients.
You may also be interested in...
OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.
OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”